NPC1L1 and metabolic dysfunction-associated steatotic liver disease: In this context, it is important to examine whether hepatic NPC1L1 can exacerbate steatosis (an initial feature of NAFLD), and whether ezetimibe can attenuate NPC1L1‐dependent hepatic disorder.